Clinical reviewer: Dr. Sarah Boss, MD

COGNIFUL publishes this guide and is part of THE BALANCE GROUP. Its residence is in Mallorca, Spain, not the United States. The selected comparisons illustrate different care models rather than an independent ranking of equivalent luxury programs. Current services, access, and suitability should be confirmed directly. [1] [2]

The CDC describes cannabis use disorder through patterns such as difficulty controlling use, unsuccessful attempts to reduce it, craving, and effects on responsibilities or relationships. These experiences need assessment in context. A familiar product or a person’s ability to maintain some responsibilities does not settle whether treatment would be useful. [3]

Describe frequency, product type, known potency, route of use, and other substances or medications. Explain uncertainty rather than guessing about contents. COGNIFUL’s cannabis pathway considers these details alongside sleep, mood, and functioning. The point is to understand the actual pattern rather than select care from a product label alone. [1]

Ask what cannabis currently provides in the person’s routine. It may be associated with relaxation, sleep, distress, social contact, or a habit that has become difficult to change. Those are possibilities to explore, not explanations to impose. A program should show how its proposed clinical work connects with the individual’s experience.

If cannabis is prescribed, involve the responsible clinician in the review. The underlying condition, expected benefit, concerns about use, and ongoing care all need consideration. Do not change prescribed treatment solely because a residential package has a fixed start date.

When products are uncertain or synthetic cannabinoids are involved, disclose that clearly. The Royal College of Psychiatrists describes a different and potentially serious risk profile for synthetic cannabinoids. A provider should assess the actual substance and symptoms rather than assume the same pathway applies to every product described as cannabis. [4]

Drug treatment may be outpatient or more intensive depending on symptoms and circumstances. Ask whether the person can attend reliably, what support is available, and how the home environment affects engagement. A residential stay should have an individual clinical rationale rather than being selected because it sounds more comprehensive. [5]

Stopping frequent cannabis use can involve sleep disruption, irritability, anxiety, low mood, or appetite changes. Those symptoms may need support and assessment. Possible psychosis, severe confusion, or an immediate safety concern needs prompt medical help, including urgent care when appropriate. Do not assume severe psychiatric symptoms are ordinary withdrawal suitable for an unassessed residence. [4]

Alcohol, sedatives, or other drugs can create separate needs. Tell the assessing team about them rather than focusing only on cannabis. COGNIFUL may require medical or psychiatric care elsewhere before admission when the residence cannot safely meet the current needs. [6]

Ask what the proposed setting adds. Outpatient care can work directly with ordinary routines. Residence provides time away and requires a later transition. The program should explain how the chosen intensity helps address the actual problem and how progress will be reviewed.

This is a set of examples rather than a national directory. UCLA is an outpatient comparison, and the cited Betty Ford Center is in Rancho Mirage rather than Los Angeles or Malibu. COGNIFUL is an international option. Accurate location affects attendance, family participation, travel, and the transition to continuing care.

WHO guidance identifies cognitive behavioral therapy, motivational enhancement, and family approaches as options for cannabis dependence, with a conditional recommendation and low-quality evidence. This supports asking about specific methods and realistic review. It does not justify a guaranteed outcome or prove that every listed provider offers each approach. [9]

Ask how goals are developed with the patient. A person may recognize costs of cannabis use while still feeling that it helps with something important. A clinician should be able to discuss that ambivalence. The treatment plan should be understandable to the person receiving care, even when relatives initiated the inquiry.

Ask what happens in sessions and how the work is practiced. Which situations, thoughts, or responses linked to use will be examined? How is a difficult attempt reviewed? A specific explanation of the process is more useful than a long therapy menu without an agreed plan.

If sleep is a central concern, ask how both the underlying problem and changes around cannabis use will be assessed. A quieter setting does not establish a clinical sleep treatment. Any medication discussion needs a qualified professional, a monitoring plan, and clarity about who continues care after the stay.

Ask how mental health needs are addressed alongside cannabis use. The Royal College of Psychiatrists advises professional support for mental health concerns and prompt assessment for possible psychosis. If several clinicians are involved, identify who coordinates the plan and how recommendations are shared with consent. [4]

Family participation should have a defined purpose and boundaries. Relatives may help with communication or planning without becoming responsible for clinical monitoring. Ask what information is shared and how the patient’s preferences guide those decisions.

Request a proposed schedule separating individual clinical work, shared activities, and other services. Ask which parts address cannabis directly and which support the residential experience. A full timetable does not demonstrate that each component fits the person’s needs; the clinical team should explain the connection.

Ask how progress is reviewed and what happens if the plan is insufficient. Relevant goals might include changes in use, functioning, engagement, or responses to difficult situations. Completion of a stay alone is not a complete outcome. The provider should describe adjustment and reassessment rather than promise that every difficulty can be anticipated.

COGNIFUL is part of THE BALANCE GROUP and offers a named cannabis addiction pathway at its Mallorca residence. Admission depends on clinical suitability and availability. Acute medical or psychiatric needs may require another service first. The program is not a US facility or an acute hospital, and travel should follow a clinical decision about readiness. [1] [6] [10]

A maximum of four clients stay in the residence at any time, each in a private suite. Clinical and bodywork sessions are individual. The residence, chef, and personal manager are shared in both programs. Other holistic sessions, excursions, and activities are shared in Premier; every session and activity is individual in Premier Plus. Both tiers follow this small shared format. Capacity alone does not establish staffing ratios, session frequency, or superior outcomes. [2]

COGNIFUL Premier and Premier Plus both include assessment, a personal plan, and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Further base-program follow-up is agreed individually. Typical stays are four to twelve weeks, with personal review rather than a cannabis recovery timetable. [11] [12] View program fees

Request the actual psychological methods, relevant clinicians, and review schedule. THE BALANCE GROUP’s shared team does not mean every listed professional participates in each admission. WHO’s treatment options are useful questions for the team, not proof that every method is included in COGNIFUL’s individual plan. Confirm the clinical work before judging the residential experience. [13] [14]

COGNIFUL is self-pay and does not directly bill insurers. US reimbursement is not guaranteed. Ask for a written total with duration assumptions, inclusions, and exclusions. Continuing care should be discussed for the actual state of residence, including receiving clinicians and medication responsibility when relevant. Plus aftercare does not establish unrestricted US telehealth or replace all local care. [11] [12]

Identify a receiving clinician or service before traveling when possible. With consent, arrange a summary of assessment, treatment, recommendations, and outstanding concerns. Ask who sends it and when the first follow-up occurs. COGNIFUL’s professional referral route can support coordination, but the actual receiving agreement must be established. [10]

Discuss time zones and appointment availability for any remote contacts or family work. A video connection is not evidence that every clinical service can be delivered in every jurisdiction. Clarify which responsibilities belong to the overseas team and which require a local professional.

Plan around work, caregiving, and other obligations. Ask what the treatment schedule requires and what communication can realistically fit. A useful program helps the person understand the demands of participation rather than assume that all responsibilities can continue unchanged.

Review the first week at home with the treating team. Which evening, social setting, or response to stress has been relevant to use? What support is available? Who can reassess if symptoms or use changes? The plan should provide realistic next steps, not depend on reproducing a residential environment indefinitely.

Ask domestic providers directly about payment and insurance arrangements for the actual policy. This guide does not establish coverage. Compare the complete proposed episode, including known travel, external services, and follow-up, rather than a residence’s weekly rate alone.

Bring previous attempts to change into the discussion. What helped, what was missing, and how does the new plan respond? A different destination or more exclusive room does not by itself explain a clinical change. The treatment and transition arrangements should do that work.

Clarify privacy through the actual handling of records, family updates, payment information, and shared spaces. If another person is arranging the stay, agree what practical information they need and what remains within the clinical relationship. The patient should understand those boundaries before admission.

Finally, ask what information is still required for a final recommendation. Keep confirmed services separate from possibilities awaiting assessment. A careful admission process can acknowledge uncertainty and identify a need for another service first; that clarity helps make the eventual decision more suitable.

Does cannabis treatment always require residential care?

No. Intensity should follow assessment and circumstances. Outpatient care may be appropriate when the person can engage with it and the setting meets the clinical needs. Ask for the rationale behind a residential recommendation. [5]

Does COGNIFUL have a US residence?

The verified residence is in Mallorca, Spain. US residents need clinical acceptance, appropriate travel planning, and a receiving arrangement at home. [2] [10]

Can cannabis-related sleep or mood problems need help?

Yes. Such concerns should be assessed, including changes around reducing use. Possible psychosis or immediate safety concerns require prompt medical attention rather than being treated as ordinary residential discomfort. [4]

What should I ask admissions first?

Request suitability assessment, the cannabis-specific treatment proposal, written fees, and a US continuing-care discussion. Share accurate product, other substance, medication, and mental health information before travel is booked. [10] [11]

1. Cannabis addiction treatment at COGNIFUL — COGNIFUL
2. Life at COGNIFUL in Mallorca — COGNIFUL
3. Understanding your risk for cannabis use disorder — Centers for Disease Control and Prevention
4. Cannabis and mental health — Royal College of Psychiatrists
5. Drug addiction: getting help — NHS
6. Clinical scope, suitability and care coordination — COGNIFUL
7. Addiction Psychiatry Clinic — UCLA Health
8. Betty Ford Center in Rancho Mirage, California — Hazelden Betty Ford Foundation
9. Psychosocial interventions for cannabis dependence — World Health Organization
10. Professional referrals — COGNIFUL
11. COGNIFUL programs, fees and admissions — COGNIFUL
12. Reintegration and continuing care — COGNIFUL
13. Clinical team and care coordination — COGNIFUL
14. How residential treatment works at COGNIFUL — COGNIFUL

Source information checked October 18, 2026. Confirm current services, eligibility, fees, and availability directly with each provider.